arrow
K

Kristina Lindemann

Oslo University Hospital
H指数:33
被引数:4,575

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PROVING THEIR WORTH: A PILOT RANDOMISED CONTROLLED FEASIBILITY AND SAFETY STUDY TESTING INDIVIDUAL ERAS INTERVENTIONS IN PERIOPERATIVE OVARIAN CANCER SURGERY - THE TIPS STUDY.

证明其价值:一项关于围手术期卵巢癌手术中个体ERAS干预措施的可行性及安全性试点随机对照研究——TIPS研究。

2026-09-210
PRE
Pragmatic gynecologic cancer clinical trials: statements and roadmap from the Gynecologic Cancer InterGroup Chicago Brainstorming Meeting

实用妇科癌症临床试验:妇科癌症协作组芝加哥头脑风暴会议的声明与路线图

2026-06-230
OAAI
Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off-the-shelf targeted NGS panel

使用现成靶向NGS面板对晚期子宫内膜癌患者进行纵向循环肿瘤DNA分析

2026-04-280
OAAI
Identifying High-Risk Relapse in Early-Stage I–II Ovarian Cancer Using the CA-125 ELIMination rate constant K (KELIM) Score: A GCIG Individual Patient Data Meta-analysis

使用CA-125 ELIMination率常数K (KELIM)评分识别早期I-II期卵巢癌的高复发风险:一项GCIG个体患者数据荟萃分析

2025-10-100
OAAI
Empowerment and quality of life in gynecological cancer survivors: Outcomes from a multicenter quasi-experimental cohort study from Norway (the LETSGO trial)

赋能和生活质量在妇科癌症幸存者中的研究:来自挪威一项多中心准实验队列研究(LETSGO试验)的结果

Cancer
IF5.1
2025-08-080
PREAI
NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer

NSGO-FANDANGO/ENGOT-EN1:一项关于在晚期/复发性子宫内膜癌中使用尼达尼布/安慰剂联合一线化疗的随机Ⅱ期研究

2025-06-300
PRE
Difference Of Chemosensitivity Between Western And Japanese Women In First-Line Setting Of Advanced Serous Ovarian Cancer: Data From The MAOV Individual Patient Data Meta-Analysis

西方与日本女性在晚期浆液性卵巢癌一线治疗中的化疗敏感性差异:来自MAOV个体患者数据Meta分析的数据

2025-02-010
PRE
Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a study

VB10.16治疗性DNA疫苗与atezolizumab联合用于持续性、复发性或转移性HPV16阳性宫颈癌的安全性和有效性:一项多中心、单臂2a期研究

2025-01-071
OA
Palbociclib plus letrozole in estrogen receptor-positive advanced/ recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial

帕博西利联合来曲唑在雌激素受体阳性晚期/复发性子宫内膜癌中的应用:双盲安慰剂对照随机II期ENGOT-EN3/PALEO试验

2025-01-011
OAAI
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed high-risk, locally advanced cervical cancer (ENGOT-cx11/ GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

Pembrolizumab或安慰剂联合放化疗,然后用pembrolizumab或安慰剂治疗新诊断的高危局部晚期宫颈癌 (ENGOT-cx11/ GOG-3047/KEYNOTE-A18): 一项随机,双盲,安慰剂对照的3期试验的总生存期结果

LANCET
IF88.5
2024-10-016
PRE
Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): A Randomized, Double-Blind, Phase 3 Clinical Trial

Pembrolizumab或安慰剂联合放化疗,然后用Pembrolizumab或安慰剂治疗新诊断的高危局部晚期宫颈癌 (ENGOT-cx11/GOG-3047/KEYNOTE-A18): 一项随机,双盲,3期临床试验

2024-09-010
PRE